GleamWall
中文EN

MPLT MapLight Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1770069 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-145.1%
TTM EPS YoY162.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-293.7%
ROA-68.6%
ROIC (approx.)-812.4%
Asset turnover—

Leverage & solvency

Liabilities / assets6.6%
Debt / equity0.00x
Current ratio9.53x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-20.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$44.21M$53.44M$53.68M$64.62M$27.09M$26.85M$19.79M$20.71M
SG&A expense$11.13M$10.11M$10.82M$18.75M$4.40M$3.82M$3.76M$2.06M
Operating income-$55.34M-$63.55M-$64.50M-$83.38M-$31.50M-$30.66M-$23.54M-$22.78M
Net income-$51.62M-$60.19M-$60.67M-$79.55M-$29.42M-$29.84M-$22.34M-$21.23M
EBITDA-$55.21M-$63.40M-$64.34M-$83.24M-$31.40M-$30.53M-$23.38M-$22.58M
EPS (basic)-0.97-1.32-1.34—-37.18-39.11-29.33—
EPS (diluted)-0.97-1.32-1.34—-37.18-39.11-29.33—
Weighted avg. shares (diluted)53.10M45.43M45.28M—791,127763,044761,598—
Balance sheet
Cash & equivalents$55.57M$71.63M$55.71M$46.73M$64.15M——$38.25M
Short-term investments$228.51M$233.09M$254.41M$258.37M$163.02M——$70.54M
Current assets$294.60M$318.79M$327.23M$324.67M$245.31M——$114.60M
PP&E, net$722,000$828,000$968,000$1.09M$859,000——$1.21M
Total assets$477.18M$368.35M$418.79M$479.51M$257.22M——$136.92M
Current liabilities$30.90M$19.29M$14.28M$16.23M$18.56M——$15.92M
Total liabilities$31.41M$20.05M$18.95M$21.14M$23.71M——$21.72M
Shareholders' equity$445.77M$348.30M$399.83M$458.37M-$274.18M-$245.06M-$215.83M-$193.63M
Shares outstanding55.67M45.44M45.21M44.02M808,015——761,276
Cash flow statement
Operating cash flow-$35.68M-$44.87M-$51.18M-$46.83M-$31.79M-$33.97M-$25.55M-$21.49M
Capital expenditure$12,000$22,000$24,000$376,000$31,000——$106,000
Free cash flow-$35.69M-$44.89M-$51.20M-$47.20M-$31.82M——-$21.59M
Investing cash flow-$130.07M$60.70M$67.01M-$242.55M-$135.59M$17.43M$37.50M$32.39M
Financing cash flow$150.55M$92,000-$6.85M$271.96M$198.06M-$156,000-$47,000$5,000
Depreciation & amortization$135,000$147,000$162,000$140,000$100,000$136,000$166,000$194,000
Stock-based compensation$10.26M$8.63M$9.64M$35.52M$125,000$148,000$212,000$214,000

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.